WINTON GROUP Ltd Makes New Investment in LivaNova PLC (NASDAQ:LIVN)

WINTON GROUP Ltd purchased a new stake in LivaNova PLC (NASDAQ:LIVN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 20,536 shares of the company's stock, valued at approximately $951,000.

Several other large investors have also recently modified their holdings of the business. Artisan Partners Limited Partnership bought a new position in LivaNova during the 4th quarter worth approximately $21,340,000. Prudential Financial Inc. increased its position in shares of LivaNova by 10.7% during the fourth quarter. Prudential Financial Inc. now owns 155,227 shares of the company's stock worth $7,189,000 after buying an additional 14,950 shares during the period. Emerald Advisers LLC raised its stake in LivaNova by 8.2% during the fourth quarter. Emerald Advisers LLC now owns 752,540 shares of the company's stock worth $34,850,000 after buying an additional 57,035 shares during the last quarter. Vanguard Group Inc. lifted its holdings in LivaNova by 12.7% in the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after buying an additional 265,291 shares during the period. Finally, Fox Run Management L.L.C. lifted its holdings in LivaNova by 183.7% in the fourth quarter. Fox Run Management L.L.C. now owns 19,843 shares of the company's stock valued at $919,000 after buying an additional 12,848 shares during the period. Institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LIVN. The Goldman Sachs Group lowered their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Needham & Company LLC reiterated a "buy" rating and issued a $64.00 target price on shares of LivaNova in a report on Monday, March 17th. Barclays dropped their price target on LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a research note on Friday, March 7th. Stifel Nicolaus reduced their price objective on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Finally, Wolfe Research downgraded shares of LivaNova from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, LivaNova presently has a consensus rating of "Buy" and a consensus target price of $61.17.

Remove Ads

LivaNova Stock Performance

LIVN traded down $2.08 during trading hours on Thursday, hitting $37.42. The stock had a trading volume of 168,308 shares, compared to its average volume of 609,110. The stock has a market cap of $2.03 billion, a PE ratio of 89.10 and a beta of 1.10. LivaNova PLC has a 1 year low of $36.85 and a 1 year high of $64.48. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The company's fifty day simple moving average is $43.94 and its 200 day simple moving average is $48.29.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.